Xiaoyan W. Li

28 Fuxing Road
Haidian, 100853, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 61 publications

Effectiveness and Safety of Trastuzumab Deruxtecan in Chinese Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer (RERUN): Study Protocol for a Real-World, Multicenter, Prospective, Observational Study.

Effectiveness and Safety of Trastuzumab Deruxtecan in Chinese Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer (RERUN): Study Protocol for a Real-World, Multicenter, Prospective, Observational Study.

Journal: Advances in therapy

Published: May 15, 2026

Development and validation of a risk-stratification model for individualized management of leptomeningeal metastases in EGFR- mutant NSCLC (LM-Index).

Development and validation of a risk-stratification model for individualized management of leptomeningeal metastases in EGFR- mutant NSCLC (LM-Index).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: April 15, 2026

Pathogenicity prediction for noncanonical splice-altering variants based on multimodal feature fusion.

Pathogenicity prediction for noncanonical splice-altering variants based on multimodal feature fusion.

Journal: Briefings in bioinformatics

Published: February 11, 2026

Immune checkpoint inhibitor-related encephalitis overlapping with hyperprogression in metastatic lung cancer: a case report.

Immune checkpoint inhibitor-related encephalitis overlapping with hyperprogression in metastatic lung cancer: a case report.

Journal: Frontiers in immunology

Published: October 19, 2025

Multi-omics analysis reveals ACOT1 as the key target of piperine in Piper Longum-mediated gastric cancer treatment.

Multi-omics analysis reveals ACOT1 as the key target of piperine in Piper Longum-mediated gastric cancer treatment.

Journal: Chinese medicine

Published: May 30, 2025

Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.

Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.

Journal: Cancer biology & medicine

Published: April 09, 2025

Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial.

Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial.

Journal: The Lancet. Respiratory medicine

Published: February 19, 2025

Immune-inflammatory markers and clinical characteristics as predictors of the depth of response and prognosis of patients with PD-L1 ≥50% metastatic non-small cell lung cancer receiving first-line immunotherapy.

Immune-inflammatory markers and clinical characteristics as predictors of the depth of response and prognosis of patients with PD-L1 ≥50% metastatic non-small cell lung cancer receiving first-line immunotherapy.

Journal: Thoracic cancer

Published: April 21, 2024

Expert consensus on the diagnosis and treatment of RET gene fusion non-small cell lung cancer in China.

Expert consensus on the diagnosis and treatment of RET gene fusion non-small cell lung cancer in China.

Journal: Thoracic cancer

Published: August 23, 2023

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK-029A in Treatment-Naive Patients With Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations: A Phase 1 Trial.

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK-029A in Treatment-Naive Patients With Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations: A Phase 1 Trial.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: July 30, 2023

Thyroid transcription factor 1 (TTF-1) negativity as a predictor of unfavorable response to EGFR-TKI therapy in advanced lung adenocarcinoma patients with EGFR mutations.

Thyroid transcription factor 1 (TTF-1) negativity as a predictor of unfavorable response to EGFR-TKI therapy in advanced lung adenocarcinoma patients with EGFR mutations.

Journal: Thoracic cancer

Published: July 12, 2023

Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer.

Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer.

Journal: Thoracic cancer

Published: November 03, 2022

Showing 1-12 of 61

Last Updated: 09/26/2026